851984-15-1

Basic information

• Product Name: 4-Amino-6-chloro-5-fluoropyrimidine
• Synonyms: 4-Amino-6-chloro-5-fluoropyrimidine;6-Chloro-5-fluoropyrimidin-4-amine;5-Amino-6-chloro-5-fluoropyrimidine;4-chloro-5-fluoro-6-aminopyrimidine;4-Pyrimidinamine, 6-chloro-5-fluoro-
• CAS NO: 851984-15-1
• Molecular Formula: C₄H₃ClFN₃
• Molecular Weight: 147.5381232
• Product Categories: pyrimidine;Fluorine series
• Mol File: 851984-15-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 275.2±35.0℃ (760 Torr)
• Flash Point: 120.3±25.9℃
• Appearance: /
• Density: 1.564±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.27±0.10(Predicted)
• CAS DataBase Reference: 4-Amino-6-chloro-5-fluoropyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-6-chloro-5-fluoropyrimidine(851984-15-1)
• EPA Substance Registry System: 4-Amino-6-chloro-5-fluoropyrimidine(851984-15-1)

Safety Data

• Safety Statements: 24/25
• HazardClass: IRRITANT-HARMFUL, AVOID SKIN CON
• Hazardous Substances Data: 851984-15-1(Hazardous Substances Data)

Usage

General Description

4-Amino-6-chloro-5-fluoropyrimidine is a chemical compound with the molecular formula C4H3ClFN3. It is a heterocyclic organic compound, belonging to the pyrimidine group, and is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 4-Amino-6-chloro-5-fluoropyrimidine is often utilized as a building block for the production of various drugs due to its ability to participate in numerous chemical reactions. Additionally, its fluorinated and chlorinated properties offer it unique characteristics that make it valuable in organic synthesis. Overall, 4-Amino-6-chloro-5-fluoropyrimidine plays a significant role in the pharmaceutical and agricultural industries.

Upstream product

• 213265-83-9 4,6-dichloro-5-fluoropyrimidine 

Downstream Products

• 1271806-79-1 (3'R,5'S)-1'-(6-amino-5-fiuoropyrimidin-4-yl)-3-(3-chloro-5-fluorophenylamino)-5'-fluoro-1,3'-bipiperidin-2-one 
• 1271808-06-0 C₂₀H₂₃Cl₂FN₆O₂ 
• 1271808-08-2 1-(4-(6-amino-5-fluoropyrimidin-4-yl)-1,4-oxazepan-6-yl)-3-(3-chloro-5-fluorophenylamino)piperidin-2-one 
• 1365992-20-6 2,6-dichloro-N-(6-chloro-5-fluoropyrimidin-4-yl)benzamide 
• 1510829-06-7 trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 
• 1510832-36-6 C₂₁H₂₃ClF₄N₆O₂ 
• 1510829-06-7 trans-1‘-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3‘-bipiperidine]-4’-carboxamide 

Relevant articles and documents

Heterocyclic compound used as MNK inhibitor

The invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method thereof, and application thereof used as a mitogen activated protein kinase interacting kinase 1 and 2-MNK1/MNK2 inhibitor. The inhibitor is the heterocyclic compound as shown in the formula (I), or its pharmaceutically acceptable salt, prodrug, solvent compound, polycrystal, isomer, stable isotope derivative or a pharmaceutical composition containing the heterocyclic compound. The compound of the invention can be used for treating or preventing MNK-mediatedrelated diseases, such as cancers.

AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of 5 manufacturing a compound of Formula I

SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN

The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1-4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.